BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTAI Stock Price Chart Interactive Chart >
BTAI Price/Volume Stats
| Current price | $12.42 | 52-week high | $36.49 |
| Prev. close | $12.84 | 52-week low | $8.80 |
| Day low | $12.21 | Volume | 385,900 |
| Day high | $13.00 | Avg. volume | 631,159 |
| 50-day MA | $12.16 | Dividend yield | N/A |
| 200-day MA | $20.26 | Market Cap | 347.57M |
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Latest BTAI News From Around the Web
Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and w |
BioXCel agitation with bipolar drug meets primary and secondary endpoints in phase 3BioXCel Therapeutics (BTAI) said that a phase 3 trial of BXCL501 (sublingual dexmedetomidine) for agitation associated with bipolar disorder demonstrated statistically significant changes. |
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar DisordersBXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo BXCL501 PDUFA Date is April 5, 2022 for acute treatment of agitation associated with schizophrenia and bipolar disorders NEW HAVEN, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in ne |
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate CancerBioXcel Therapeutics Inc (NASDAQ: BTAI ) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium. The trial is evaluating the combination of BXCL701 with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). SCNC Findings: In the evaluable patient cohort (n = 15), |
IQVIA Holdings' Q4 Beats Street View, Lifts FY22 Earnings GuidanceView more earnings on IQVSee more from BenzingaBioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate CancerHenry Schein Q4 Topline, Bottom Line Beat Street View, FY22 Outlook Exceeds Consensus© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
BTAI Price Returns
| 1-mo | N/A |
| 3-mo | -40.60% |
| 6-mo | -38.91% |
| 1-year | -59.45% |
| 3-year | 13.32% |
| 5-year | N/A |
| YTD | -38.91% |
| 2021 | -56.00% |
| 2020 | 216.22% |
| 2019 | 278.50% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...